

February 1, 2024

Name of listed company: Chugai Pharmaceutical Co., Ltd.
Code number: 4519 (Prime Market of Tokyo Stock Exchange)
Head office: 1-1, Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo
President & CEO: Osamu Okuda
Inquiries to: Kae Miyata
Head of Corporate Communications Dept.
Tel: +81-(0)3-3273-0554

Notice Regarding the Difference of Individual Financial Results as Compared to Actual Results for the Previous Year

Chugai Pharmaceutical Co., Ltd. hereby announces that there is a difference regarding the individual financial results (Japanese standard) for the year ended December 2023 (Jan. 1, 2023 – Dec. 31, 2023) as compared to the actual results for the previous year (Jan. 1, 2022 – Dec. 31, 2022).

1. The difference between the actual results for the year ended December 2023 and the actual results for the previous year

	Revenues	Operating Income	Ordinary Income	Net Income	Earnings per Share
Actual results for the previous year (A) (Jan. 1, 2022 – Dec. 31, 2022)	(millions of yen) 1,250,682	(millions of yen) 517,596	(millions of yen) 525,010	(millions of yen) 366,728	(Yen Sen) 222.96
Actual results for this year (B) (Jan. 1, 2023 – Dec. 31, 2023)	(millions of yen) 1,105,883	(millions of yen) 421,176	(millions of yen) 442,014	(millions of yen) 324,704	(Yen Sen) 197.36
Change (B-A)	(millions of yen) (144,799)	(millions of yen) (96,420)	(millions of yen) (82,996)	(millions of yen) (42,024)	-
Change (%)	(11.6)	(18.6)	(15.8)	(11.5)	-

* Income from disposal of product rights that were previously included in revenues are included in non-operating income from this year. The income of ¥220 million have been excluded from actual results for the previous year.

2. Reasons for the difference occurring

The difference occurred mainly due to major decrease in sales as a result of the supply of Ronapreve[®] to the Japanese government as well as one-time impact of recognizing the income related to the settlement agreement with Alexion Pharmaceuticals, Inc. in the previous fiscal year, despite the strong performance of new products and mainstay products in the domestic market, and increases in exports to Roche.

###